Remove 2026 Remove Compounding Remove Diabetes
article thumbnail

Bayer Pharmaceuticals accelerates innovations for patients

LifeProNow

Kerendia is already approved in major markets in chronic kidney disease (CKD) associated with type 2 diabetes. The estimated compounded annual growth rate is more than 26 percent reaching $1.36 billion in sales by 2026. Bayer has exclusive worldwide marketing rights for this product including the U.S.

Bioethics 130
article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

Global Trends in Pharmacy

RX Note

Introduction In parallel with industrialization, the focus of pharmacists' practice has evolved from compounding and dispensing medications to the provision of professional services for patients. As experts in medicines, pharmacists can review complex medicine regimens and identify causes of problems and resolve them.